Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer.
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 50 points on Monday.
Following the market opening Monday, the Dow traded up 0.15% to 37,362.28 while the NASDAQ rose 0.14% to 14,835.17. The S&P 500 also rose, gaining, 0.29% to 4,732.84.
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) rose sharply in pre-market trading after the FDA approved company’s ZORYVE topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals aged 9 years and older.